Business Description
Lipocine Inc
NAICS : 325412
SIC : 2834
ISIN : US53630X1046
Description
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.94 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 5.97 | |||||
| Beneish M-Score | 41.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 21 | |||||
| 3-Year EPS without NRI Growth Rate | 18.5 | |||||
| 3-Year FCF Growth Rate | 21.6 | |||||
| 3-Year Book Growth Rate | 1 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.12 | |||||
| 9-Day RSI | 47.46 | |||||
| 14-Day RSI | 50.62 | |||||
| 6-1 Month Momentum % | 148.03 | |||||
| 12-1 Month Momentum % | 37.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 16.99 | |||||
| Quick Ratio | 16.99 | |||||
| Cash Ratio | 16.53 | |||||
| Days Payable | 60.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -14.5 | |||||
| Operating Margin % | -220.1 | |||||
| Net Margin % | -190.36 | |||||
| FCF Margin % | -117.38 | |||||
| ROE % | -35.22 | |||||
| ROA % | -32.56 | |||||
| ROIC % | -711.26 | |||||
| ROC (Joel Greenblatt) % | -7806.91 | |||||
| ROCE % | -36.29 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.64 | |||||
| PB Ratio | 1.68 | |||||
| Price-to-Tangible-Book | 1.68 | |||||
| EV-to-EBIT | -1.81 | |||||
| EV-to-EBITDA | -1.82 | |||||
| EV-to-Revenue | 3.56 | |||||
| EV-to-FCF | -3.01 | |||||
| Price-to-Net-Current-Asset-Value | 1.69 | |||||
| Price-to-Net-Cash | 1.74 | |||||
| Earnings Yield (Greenblatt) % | -55.25 | |||||
| FCF Yield % | -13.68 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers